Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Sellas Life Sciences Group Inc (SLS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: SLS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $6.83
1 Year Target Price $6.83
| 2 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -66% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 202.17M USD | Price to earnings Ratio - | 1Y Target Price 6.83 |
Price to earnings Ratio - | 1Y Target Price 6.83 | ||
Volume (30-day avg) 3 | Beta 2.27 | 52 Weeks Range 0.77 - 2.27 | Updated Date 08/29/2025 |
52 Weeks Range 0.77 - 2.27 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.3 |
Earnings Date
Report Date 2025-08-12 | When - | Estimate -0.08 | Actual -0.07 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -68.75% | Return on Equity (TTM) -180.71% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 177611140 | Price to Sales(TTM) 26.9 |
Enterprise Value 177611140 | Price to Sales(TTM) 26.9 | ||
Enterprise Value to Revenue 20.84 | Enterprise Value to EBITDA -1.71 | Shares Outstanding 105297000 | Shares Floating 104976312 |
Shares Outstanding 105297000 | Shares Floating 104976312 | ||
Percent Insiders 0.32 | Percent Institutions 25.54 |
Upturn AI SWOT
Sellas Life Sciences Group Inc
Company Overview
History and Background
Sellas Life Sciences Group Inc. is a late-stage clinical biopharmaceutical company focused on the development of novel immunotherapies for cancer. Founded in 2012, Sellas has focused on developing immunotherapies targeting defined cancer antigens to stimulate an effective tumor-directed immune response.
Core Business Areas
- Immunotherapy Development: Focuses on developing novel cancer immunotherapies to fight cancer.
Leadership and Structure
The leadership team consists of experienced pharmaceutical executives and scientists. The company has a board of directors providing governance and strategic direction.
Top Products and Market Share
Key Offerings
- Galinpepimut-S (GPS): GPS is a heteroclitic peptide immunotherapeutic that targets Wilms' Tumor-1 (WT1), an intracellular oncogenic protein expressed in a variety of hematologic malignancies and solid tumors. It's in Phase 3 clinical trials for acute myeloid leukemia (AML). No significant market share yet as it's not commercialized. Competitors include companies developing other AML therapies, such as Novartis, Pfizer, and Bristol-Myers Squibb. Also, companies developing AML immunotherapies, but targeting different proteins.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The immunotherapy segment is experiencing rapid growth due to promising clinical results and increasing investment.
Positioning
Sellas is positioned as a specialized immunotherapy company focusing on novel cancer treatments. Its lead product, GPS, targets a validated cancer antigen and aims to provide a differentiated approach to cancer therapy.
Total Addressable Market (TAM)
The TAM for AML and other WT1-expressing cancers is significant, estimated to be in the billions of dollars. Sellas is positioned to capture a portion of this market with successful clinical development and commercialization of GPS.
Upturn SWOT Analysis
Strengths
- Novel immunotherapy approach
- Targeting a validated cancer antigen (WT1)
- Phase 3 clinical development stage
- Experienced management team
Weaknesses
- Reliance on a single lead product candidate
- High R&D expenses
- Dependence on successful clinical trial outcomes
- Limited financial resources compared to larger pharmaceutical companies
Opportunities
- Potential for accelerated regulatory approval
- Partnerships with larger pharmaceutical companies
- Expansion into other WT1-expressing cancers
- Positive clinical trial data could increase investor confidence.
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other immunotherapy companies
- Patent expiration
- Negative clinical trial data.
Competitors and Market Share
Key Competitors
- JNJ
- BMY
- PFE
Competitive Landscape
Sellas faces intense competition from larger pharmaceutical companies with established presence in the oncology market. Its competitive advantage lies in its novel immunotherapy approach and targeting of WT1.
Growth Trajectory and Initiatives
Historical Growth: Growth is tied to the advancement of GPS through clinical trials.
Future Projections: Future growth depends on the successful completion of Phase 3 trials and subsequent regulatory approval and commercialization of GPS. Analyst estimates vary depending on the perceived probability of success.
Recent Initiatives: Focus on advancing GPS through Phase 3 clinical trials and exploring potential partnerships for commercialization.
Summary
Sellas Life Sciences Group is a clinical-stage biopharmaceutical company focused on cancer immunotherapy. Its lead product, GPS, is in Phase 3 trials for AML, representing a significant potential opportunity if successful. However, the company faces risks associated with clinical trial outcomes, regulatory approvals, and competition. Financial stability and strategic partnerships are crucial for its long-term success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
The information provided is for informational purposes only and should not be considered as investment advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share information is based on estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sellas Life Sciences Group Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2017-12-29 | Founder, President, CEO & Director Dr. Angelos M. Stergiou M.D., ScD h.c. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 15 | |
Full time employees 15 | |||
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.